Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics.

about

Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics.

Item

http://www.wikidata.org/entity/Q45327788

description

2017 nî lūn-bûn

@nan

2017 թվականի հոկտեմբերին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics.

@en

Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics.

@nl

type

Item

label

Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics.

@en

Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics.

@nl

prefLabel

Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics.

@en

Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics.

@nl

P1476

Drug screening to target nuclear orphan receptor NR4A2 for cancer therapeutics.

@en

P2093

Anuradha Roy

http://www.w3.org/2001/XMLSchema#string

Peter McDonald

http://www.w3.org/2001/XMLSchema#string

Raymond P Perez

http://www.w3.org/2001/XMLSchema#string

Satomi Yamamoto

http://www.w3.org/2001/XMLSchema#string

Takefumi Komiya

http://www.w3.org/2001/XMLSchema#string

P2860

Transducer of regulated CREB-binding proteins (TORCs) induce PGC-1alpha transcription and mitochondrial biogenesis in muscle cells

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway

Sustained expression of Mect1-Maml2 is essential for tumor cell growth in salivary gland cancers carrying the t(11;19) translocation

Heterodimerization between members of the Nur subfamily of orphan nuclear receptors as a novel mechanism for gene activation

Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice.

P304

600-610

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/TLCR.2017.07.02

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29114475

http://www.w3.org/2001/XMLSchema#string

P932

5653521

http://www.w3.org/2001/XMLSchema#string